RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).

Esophageal Adenocarcinoma Clinical Trial

— ROBOT-2  

Official title:

Robot-assisted Minimally Invasive Thoraco-laparoscopic Esophagectomy Versus Minimally Invasive Esophagectomy for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04306458
• Other study ID #: ROBOT2 trial
• Status: Recruiting
• Phase: N/A
• Start date: January 18, 2021
• Est. completion date: January 19, 2028

Study information

• Verified date: May 2022
• Source: University Medical Center Mainz
• Contact: Pieter Christiaan van der Sluis, MD,PhD
• Phone: +31628880709
• Email: p.c.vandersluis-2[@]umcutrecht.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

BACKGROUND: For patients with esophageal cancer, radical esophagectomy with 2-field lymphadenectomy is the cornerstone of the multimodality treatment with curative intent. Both, conventional minimally invasive esophagectomy (MIE) and robot assisted minimally invasive esophagectomy (RAMIE) were shown to be superior compared to open transthoracic esophagectomy considering postoperative complications. However, no randomized comparison was made until now to compare MIE to RAMIE

OBJECTIVES: The objective is to evaluate the extent of lymph node dissection, efficacy, risks, quality of life and cost-effectiveness of RAMIE as an alternative to MIE as treatment for esophageal adenocarcinoma or adenocarcinoma of the gastroesophageal junction..

METHODS: This is an investigator-initiated and investigator-driven multicenter randomized controlled parallel-group, superiority trial. All adult patients (age ≥18 and ≤ 90 years) with histologically proven, surgically resectable (cT1-4a, N0-3, M0) adenocarcinoma of the intrathoracic esophagus or adenocarcinoma of the gastroesophageal junction with European Clinical Oncology Group performance status 0, 1 or 2 will be assessed for eligibility and included after obtaining informed consent. Patients (n=218) are randomized at the outpatient department to either RAMIE (n=109) or MIE (n=109). The primary outcome of this study is the total number of resected lymph nodes according to the TIGER classification for esophageal cancer lymphadenectomy.

CONCLUSION: This is the first randomized controlled trial designed to compare RAMIE to MIE as surgical treatment for resectable adenocarcinoma of the intrathoracic esophagus or adenocarcinoma of the gastroesophageal junction in the Western World. If our hypothesis is proven correct, RAMIE will result in a better lymph node dissection compared to conventional MIE. The study started in September 2019. Follow up will be 5 years. Short term results will be analyzed and published after discharge of the last randomized patient.

Description:

Aim of the study This is a randomized controlled parallel-group, superiority trial comparing RAMIE to MIE with intrathoracic anastomosis (Ivor-Lewis) in patients with resectable esophageal adenocarcinoma or adenocarcinoma of the gastroesophageal junction in the Western World.

Methods Objectives Patients with resectable esophageal adenocarcinoma or adenocarcinoma of the gastroesophageal junction are randomized at the outpatient department to either (a) robot-assisted minimally invasive esophagectomy (RAMIE) or (b) conventional minimally invasive esophagectomy (MIE). The objective is to evaluate the extent of lymph node dissection, efficacy, risks, survival and cost-effectiveness of RAMIE as an alternative to MIE as treatment for esophageal adenocarcinoma or adenocarcinoma of the gastroesophageal junction. We hypothesize that RAMIE leads to an improved lymph node dissection compared to MIE.

Study design This is a multicenter investigator-initiated and investigator-driven randomized controlled parallel-group, superiority trial comparing RAMIE to MIE. This study is conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. The independent ethics committee of the University Medical Center of the Johannes Gutenberg University, Mainz, Germany has approved the study. Written informed consent will be obtained from all participating patients. All centers participating in the ROBOT-2 trial have extensive experience in minimally invasive esophageal surgery and have an experience with at least 50 MIE an 50 RAMIE procedures performed.

Clinical trial monitoring will be conducted by an independent data monitor from the Johannes Gutenberg University, Mainz, Germany. A Data safety monitoring board (DSMB) will evaluate safety for patients included within this trial. All outcomes will be evaluated by a (blinded) external independent data committee board for the Upper GI International Robotic association (UGIRA).

Study protocol Patients are informed about the trial by one of our surgeons at the outpatient department. After receiving the information, all patients get one week time to consider their consent. After obtaining informed consent, randomization, with concealment of allocation, is done centrally by an online randomization program. There is no blinding for the patient, surgeon and coordinating researcher because this is difficult in daily practice. However the UGIRA committee and DSMB are blinded to the allocated intervention. This study is funded by Intuitive surgical Inc., Sunnyvale, CA, USA. Neoadjuvant (radio)chemotherapy will be administered according to current international policy. Multiple esophageal cancer biopsies for pathological analysis will be obtained through esophagogastroscopy of which 4 biopsies will be snap frozen and stored for translational research. All resection specimens will be preserved and stored (biobank) for translational research. The study will start on April 1st 2020. Inclusion will take approximately 2 years. Follow up for each patient will be 5 years. Total duration of the study will be 7 years.

Surgery All procedures (RAMIE or MIE) will be carried out by experienced surgeons with experience of at least 50 MIE and 50 RAMIE procedures. All patients will receive an epidural catheter to provide adequate postoperative analgesia. Patients will be intubated with a left-sided double-lumen tube to enable selective desufflation of the right lung during the thoracic phase in both procedures.

Antibiotic prophylaxis (Ampicillin 2000 mg and Sulbactam 1000mg) will be administered 30 minutes prior to incision. A thoracic drain will be positioned in the right hemithorax at the end of the procedure. Extubating will take place in the operating theater directly postoperatively and hereafter all patients will be admitted to the intensive care unit (ICU) for hemodynamic and respiratory monitoring. Hemodynamical and respiratory stable patients were discharged towards the surgical ward. All patients were placed on a nil-by-mouth routine for the first 3 days postoperatively. In absence of clinical signs of anastomotic insufficiency, patients started with sips of water and the oral intake was gradually increased to solid food. There was no enhanced recovery program.

Surgical procedure: RAMIE The RAMIE technique using the 4 arm daVinci Xi system was described previously (daVinci Xi system, Intuitive Surgical Inc., Sunnyvale, CA, USA).20 For the abdominal phase, the patient is placed in supine position. Robotic trocars positions are shown in figure 2a. The lesser omentum is opened and transected closely to the liver, until the left crus of the diaphragm is reached. Hereafter, the greater gastric curvature is dissected. An abdominal lymphadenectomy is performed including lymph nodes surrounding the hepatoduodenal ligament, the celiac trunk, along the left gastric and splenic artery and the lesser omental lymph nodes. The left gastric artery and vein are ligated with robotic Hem-o-lok and transected at their origin. The gastric conduit is created at the level of the crow's foot using a (robotic) endostapler .

For the thoracic phase, the patient is positioned in the left lateral decubitus position, tilted 45° towards the prone position (semi-prone). Trocars positions are shown in figure 3a. The robotic system is brought into the field at the dorsocranial side of the patient. After incision and installation of the operation robot and selective desufflation of the right lung, the pulmonary ligament is divided. Hereafter, the parietal pleura is dissected at the anterior side of the esophagus from the diaphragm up to the azygos arch. The azygos vein is ligated with robotic Hem-o-lok and divided. Dissection of the parietal pleura is continued above the azygos arch to establish dissection of the right paratracheal lymph nodes. At the posterior side of the esophagus, the parietal pleura is dissected cranially to caudally along the azygos vein, including the thoracic duct. The thoracic duct is clipped with robotic Hem-o-lok to prevent chylous leakage. The esophagus is resected en bloc with the surrounding mediastinal lymph nodes. The gastric conduit is pulled up and the specimen is removed through a small incision (mini-thoracotomy) at the location of the trocar in the 6th intercostal space. Continuity is created with a circular stapled esophago-gastrostomy, which is routinely oversewn with a V-Lock (Medtronic). An omental wrap around the anastomosis is created in all patients.

Surgical procedure: MIE For the abdominal phase, the patient is placed in supine French position. The lesser omentum is opened and transected closely to the liver, until the left crus of the diaphragm is reached. Hereafter, the greater gastric curvature is dissected. An abdominal lymphadenectomy is performed including lymph nodes surrounding the hepatoduodenal ligament, the celiac trunk, along the left gastric and splenic artery and the lesser omental lymph nodes. The left gastric artery and vein are ligated with clips and transected at their origin. The gastric conduit is created at the level of the crow's foot using an endostapler For the thoracic phase, the patient is positioned in the left lateral decubitus position, tilted 45° towards the prone position (semi-prone). After selective desufflation of the right lung, the pulmonary ligament is divided. Hereafter, the parietal pleura is dissected at the anterior side of the esophagus from the diaphragm up to the azygos arch. The azygos vein is ligated with an Endostapler or clips. Dissection of the parietal pleura is continued above the azygos arch to establish dissection of the right paratracheal lymph nodes. At the posterior side of the esophagus, the parietal pleura is dissected cranially to caudally along the azygos vein, including the thoracic duct. The thoracic duct is clipped with a clips to prevent chylous leakage. The esophagus is resected en bloc with the surrounding mediastinal lymph nodes.

The gastric conduit is pulled up and the resection specimen is removed through a small incision (mini-thoracotomy) at the location of the trocar in the 6th intercostal space. Continuity is created using stapled esophago-gastrostomy, which is routinely oversewn with a V-Lock (Medtronic). An omental wrap around the anastomosis is created in all patients.

Statistical analysis All prospective data will be statistically analyzed by the use of the statistical software SPSS. All analyses were performed according to the intention-to-treat (ITT) principle. Results are presented as risk ratios with corresponding 95% confidence intervals (CI). To evaluate significance of differences between groups, the chi-squared test was used as appropriate for categorical variables and the student's T-test and non-parametric Mann-Whitney U-test for continuous variables.

Differences over time in quality of life and pain scores between and within treatment groups were assessed using linear mixed-effects models adjusted for the baseline value. Overall and progression-free survival curves were estimated with the Kaplan-Meier method and compared with the log-rank test. All reported P-values were two-sided. Significance level was set at 0.05.

The cost-effectiveness analysis will compare the mean costs and effects for both strategies and result in an incremental cost-effectiveness ratio. Uncertainty in the balance between costs and effects will be assessed with bootstrapping. A time horizon of 5 years will be applied, and costs and effects will be discounted according to Dutch guidelines.

If the baseline characteristics differ after randomization, i.e. there is a lack of balance in the confounding factors; this will be corrected using the multivariate analysis or by using a net benefit regression approach.

Interim-analysis There will be one interim-analysis. The stopping rule used for efficacy (i.e. better outcome for minimally invasive for the primary endpoint) is the Peto-approach, meaning a p-value <0.001. The trial will not be stopped for futility (i.e. no difference) and there is no there is no formal stopping rule for harm.

After every 50 patients, individualized patient description charts including safety parameters will be presented to the UGIRA Data Safety Monitoring Board (DSMB). The DSMB will discuss these in a plenary, telephone or online conference with the study coordinator and principal investigator present. The trial research group will discuss in a plenary session together with the DSMB the potential harm per patient and determine whether a relationship can be drawn between the surgical procedure and the adverse events. Consensus will be reached and the Institutional ethical board will be informed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 218
• Est. completion date: January 19, 2028
• Est. primary completion date: May 19, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Histologically proven adenocarcinoma of the intrathoracic esophagus and gastroesophageal junction (including Siewert I and II)

• Surgically resectable (T1-4a, N0-3, M0)

• Age = 18 and = 90 years

• European Clinical Oncology Group (ECOG) performance status 0,1 or 2

• Written informed consent

Exclusion Criteria:

• Esophageal squamous cell carcinoma

• Carcinoma of the cervical esophagus

• Carcinoma of the gastro-esophageal junction (GEJ) with the main part of the tumor in the gastric cardia (Siewert type III)

• Prior thoracic surgery at the right hemithorax or thoracic trauma

Related Conditions & MeSH terms

• Esophageal Adenocarcinoma
• Esophageal Neoplasms

Intervention

Procedure:
• Minimally invasive esophagectomy
Conventional minimally invasive esophagectomy

Device:
• daVinci Xi system
robot assisted minimally invasive esophagectomy

Locations

Country	Name	City	State
Germany	University Medical Center Mainz	Mainz

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Mainz

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total number of dissected lymph nodes	Total number of dissected lymph nodes in the resection specimen according to the TIGER classification	Up to 2 weeks postoperatively
Secondary	Postoperative complications	Postoperative complications and specific complications	Operation date till date of discharge until 52 weeks postoperatively
Secondary	Length of intensive care unit (ICU) and hospital stay	Days in the ICU and hospital	Operation date till date of discharge until 52 weeks postoperatively
Secondary	In hospital mortality (IHM)	30, 60 and 90 day mortality	Hospital admission period up to 90 days postoperatively
Secondary	Pathology results	Radical resection (R0 and R1)	Up to 2 weeks postoperatively
Secondary	Survival	Overall and disease free survival (2,3 and 5 year)	5 years postoperatively
Secondary	Operation statistics	Operating time (thoracic, abdominal and total), blood loss, intraoperative complications	day of operation
Secondary	Postoperative pain	Postoperative pain scores on a visual analogue scale (VAS)	Before operation (baseline), daily during admission in the first 14 days, postoperatively: 6 weeks, 6 months and yearly post-operatively up to 5 years
Secondary	Cost analysis	Cost analysis	date of operation until 1 year postoperatively
Secondary	Surgeons fatigue	Surgeons fatigue directly after Operation assessed by Psychomotor Vigilance tests (PVT) before and after esophagectomy	Day of operation
Secondary	Quality of life after esophagectomy	Quality of life assessed by questionnaire European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30	Before operation (baseline), at discharge, postoperatively: 6 weeks, 6 months and yearly up to 5 years post-operatively
Secondary	Postoperative Recovery	Dutch discharge criteria (removal of thoracic tubes, no requirement of intravenous fluid resuscitation, tolerance for solid oral intake, the ability to mobilize independently and adequate pain control with oral analgesics)	14 days postoperatively
Secondary	Quality of life after esophagectomy	Quality of life assessed by questionnaire European Organisation for Research and Treatment of Cancer (EORTC OES18)	Before operation (baseline), at discharge, postoperatively: 6 weeks, 6 months and yearly up to 5 years post-operatively
Secondary	Quality of life after esophagectomy	Quality of life assessed by questionnaire Short Form (SF)-36	Before operation (baseline), at discharge, postoperatively: 6 weeks, 6 months and yearly up to 5 years post-operatively
Secondary	Quality of life after esophagectomy	Quality of life assessed by questionnaire EuroQol (EQ)-5D	Before operation (baseline), at discharge, postoperatively: 6 weeks, 6 months and yearly up to 5 years post-operatively